GlassScriptPhysician profile
Earl S Young
NPI 1639151830
$1,553.28
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $393 · 2021: $699 · 2022: $246 · 2023: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $113.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $308.62 | 2020-2023 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.48 | 2019-2022 | |
| Harmony Biosciences LLC | $195.22 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $141.54 | 2020-2022 | |
| Fisher & Paykel Healthcare INC | $136.99 | 2021-2022 | |
| Ucb, INC. | $103.56 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $92.25 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $61.28 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $52.09 | 2021 | |
| Bausch Health US, LLC | $46.84 | 2020-2021 | |
| Grifols USA, LLC | $37.61 | 2019-2021 | |
| Mylan Specialty L.P. | $36.60 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $29.64 | 2021 | |
| Gilead Sciences, INC. | $25.32 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $16.87 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $15.70 | 2021 | |
| Genzyme Corporation | $12.02 | 2021 | |
| Phadia US INC. | $11.68 | 2021 | |
| Merck Sharp & Dohme LLC | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earl Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.